A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
- Registration Number
- NCT03090100
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
- Detailed Description
The study consists of Screening Phase(4 weeks before administration of study drug),Active Treatment Phase(Week 0-Week 44),Follow Up Phase(Week 44-Week 56).During various study periods,safety assessments(example\[e.g\] recording of adverse events,Vital signs,Tuberculosis evaluation,Chest radiograph,Urine pregnancy Test);Efficacy assessments(e.g IGA,PASI);Clinical Laboratory Assessments(e.g haematology,chemistry);Biomarkers/Genetic evaluations,will be performed per the study procedures.The primary hypotheses are that guselkumab treatment is non-inferior to secukinumab as assessed by proportion of participants achieving PASI 90 response at Week 48 with noninferiority margin of 10% and,once non-inferiority is established,that guselkumab is superior to secukinumab as assessed by proportion of participants achieving PASI 90 response at Week 48.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1048
- Have a diagnosis of plaque-type psoriasis (with or without [Psoriatic Arthritis]PsA) for at least 6 months before the first administration of study drug
- A woman of childbearing potential must have a negative urine pregnancy test at screening and at Week 0 and agree to urine pregnancy testing before receiving injections
- Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
- Agree not to receive a Bacille Calmette-Guérin (BCG) vaccination during the study, or within 12 months after the last administration of study drug
- Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study
- Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Has previously received guselkumab or secukinumab
- Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
- Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly
- Is unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group I: Guselkumab Plus Placebo Placebo Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind. Group II: Secukinumab Secukinumab Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44. Group I: Guselkumab Plus Placebo Guselkumab Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48 Week 48 The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48 Week 48 The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved a PASI-90 Response at Week 16 Week 16 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16 Week 48 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90 percent (%) reduction in PASI relative to baseline.
Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48 Week 12 and 48 Percentage of participants who achieved PASI-75 response at both Week 12 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Percentage of Participants Who Achieved a PASI-90 Response at Week 12 Week 12 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Due to failing to achieve superiority of prior secondary endpoint, no formal statistical testing was performed for endpoints from this point onwards.
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48 Week 48 The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved a PASI-75 Response at Week 16 Week 16 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12 Week 12 The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12 Week 48 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Percentage of Participants Who Achieved a PASI-75 Response at Week 12 Week 12 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.
Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48 Week 16 and 48 Percentage of participants who achieved PASI-90 response at both Week 16 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.
Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48 Week 24 up to Week 48 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Percentage of participants who achieved a PASI-90 response at all 7 visits from Week 24 to 48 (Week 24, 28, 32, 36, 40, 44 and 48) was reported.
Percentage of Participants With IGA Responses Through Week 56 Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56 The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved a PASI-100 Response at Week 48 Week 48 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 100 response was defined as 100% reduction in PASI relative to baseline.
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16 Week 16 The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Percentage of Participants Who Achieved PASI Response (PASI 100, PASI-90, PASI-75 and PASI-50) Over Time From Week 1 to Week 56 Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56 PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively.
Percent Improvement From Baseline in PASI Through Week 56 Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and Week 56 The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Trial Locations
- Locations (141)
Dermatologicka ambulance
🇨🇿Svitavy, Czechia
Indiana Clinical Trial Center
🇺🇸Plainfield, Indiana, United States
Central Dermatology
🇺🇸Saint Louis, Missouri, United States
Arlington Dermatology
🇺🇸Rolling Meadows, Illinois, United States
Dermatologists of Greater Columbus
🇺🇸Bexley, Ohio, United States
Guenther Dermatology Research Centre
🇨🇦London, Ontario, Canada
Sinclair Dermatology
🇦🇺East Melbourne, Australia
Skin&Cancer Foundation Inc
🇦🇺Melbourne, Australia
Veracity Clinical Research
🇦🇺Woolloongabba, Australia
Woden Dermatology
🇦🇺Woden, Australia
Nemocnice Jihlava
🇨🇿Jihlava, Czechia
Fremantle Dermatology
🇦🇺Fremantle, Australia
St George Dermatology & Skin Cancer Centre
🇦🇺Kogarah, Australia
Nemocnice Novy Jicin a.s.
🇨🇿Novy Jicin, Czechia
Fakultni nemocnice Ostrava
🇨🇿Ostrava- Poruba, Czechia
Royal Melbourne Hospital
🇦🇺Parkville, Australia
Clinical Trials SA Pty Ltd
🇦🇺Hectorville, Australia
Windsor Dermatology
🇺🇸East Windsor, New Jersey, United States
Academic Dermatology Associates
🇺🇸Albuquerque, New Mexico, United States
Clinical Partners
🇺🇸Johnston, Rhode Island, United States
Dermatology Consulting Services, PLLC
🇺🇸High Point, North Carolina, United States
Virginia Clinical Research
🇺🇸Norfolk, Virginia, United States
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha, Czechia
Dr. Chih-ho Hong Medical
🇨🇦Surrey, Canada
Kozni ambulance Kutna Hora, s.r.o.
🇨🇿Kutna Hora, Czechia
Premier Specialists
🇦🇺Kogarah, Australia
Westmead Hospital
🇦🇺Westmead, Australia
The Skin Centre
🇦🇺Benowa, Australia
Innovaderm Research
🇨🇦Montreal, Canada
Universitatsklinikum Essen
🇩🇪Essen, Germany
Hosp. Univ. Fundacion Alcorcon
🇪🇸Alcorcon, Spain
Masarykova nemocnice v Usti nad Labem
🇨🇿Usti Nad Labem, Czechia
Hosp. Univ. de Cruces
🇪🇸Barakaldo, Spain
ICH Hopital A. Morvan
🇫🇷Brest, France
CHU Nantes - Hotel Dieu
🇫🇷Nantes, France
Hosp. Univ. Germans Trias I Pujol
🇪🇸Badalona, Spain
Hopital Larrey CHU de Toulouse
🇫🇷Toulouse, France
Medmare Egeszsegugyi Es Szolgaltato Bt.
đź‡đź‡şVeszprem, Hungary
Hosp. Del Mar
🇪🇸Barcelona, Spain
Szegedi Tudomanyegyetem
đź‡đź‡şSzeged, Hungary
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. Univ. de Torrejon
🇪🇸Madrid, Spain
Minnesota Clinical Study Center
🇺🇸Fridley, Minnesota, United States
The Ohio State University
🇺🇸Gahanna, Ohio, United States
Dermatology Specialists
🇺🇸Louisville, Kentucky, United States
San Luis Dermatology & Laser Clinic, Inc
🇺🇸San Luis Obispo, California, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Atlanta Dermatology, Vein & Research Center
🇺🇸Alpharetta, Georgia, United States
DERMAMEDICA s.r.o.
🇨🇿Nachod, Czechia
Hopital Charles Nicolle
🇫🇷Rouen, France
Universitaetsklinikum Muenster
🇩🇪Muenster, Germany
Somogy Megyei Kaposi Mor Oktatokorhaz
đź‡đź‡şKaposvar, Hungary
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
đź‡đź‡şMiskolc, Hungary
Markusovszky Egyetemi Oktatokorhaz
đź‡đź‡şSzombathely, Hungary
CRC Sp. z o.o.
🇵🇱Poznan, Poland
Hosp. Gral. Univ. de Alicante
🇪🇸Alicante, Spain
CCA Medical Research Corporation
🇨🇦Ajax, Canada
Eastern Canada Research Associates
🇨🇦Halifax, Canada
Florida Academic Dermatology Centers
🇺🇸Coral Gables, Florida, United States
Great Lakes Research Group
🇺🇸Bay City, Michigan, United States
Centre Dermatologique
🇨🇦Quebec, Canada
Groupe Hospitalier La Rochelle - Re - Aunis
🇫🇷La Rochelle, France
CHU de Nice Hopital de l Archet
🇫🇷Nice, France
Klinische Forschung Dresden GmbH
🇩🇪Dresden, Germany
Park Avenue Dermatology
🇺🇸Orange Park, Florida, United States
Universitaetsklinik Luebeck
🇩🇪Luebeck, Germany
Universitaetsklinik Tuebingen
🇩🇪Tuebingen, Germany
Centrovital
🇩🇪Witten, Germany
Debreceni Egyetem Klinikai Kozpont
đź‡đź‡şDebrecen, Hungary
Copernicus Podmiot Leczniczy Sp. z o.o
🇵🇱Gdansk, Poland
Dermatrials Research
🇨🇦Hamilton, Ontario, Canada
ISA GmbH
🇩🇪Berlin, Germany
SCIderm GmbH
🇩🇪Hamburg, Germany
Hamzavi Dermatology
🇺🇸Fort Gratiot, Michigan, United States
DermAssociates, PC
🇺🇸Rockville, Maryland, United States
Skin Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
DermEdge Research
🇨🇦Mississauga, Canada
Stratica Medical
🇨🇦Edmonton, Canada
CHU Bordeaux - Hopital St Andre
🇫🇷Bordeaux, France
Universitatsklinikum Bonn
🇩🇪Bonn, Germany
K. Papp Clinical Research
🇨🇦Waterloo, Canada
XLR8 Medical Research
🇨🇦Windsor, Canada
Universitatsklinikum Schleswig-Holstein - Kiel
🇩🇪Kiel, Germany
Specderm Poznańska sp. j.
🇵🇱Bialystok, Poland
Solumed S.C.
🇵🇱Poznan, Poland
Le Bateau Blanc
🇫🇷Martigues, France
University Hospital Dresden
🇩🇪Dresden, Germany
Charite Universitatsmedizin Berlin, Campus Mitte (CCM) Allergie Center
🇩🇪Berlin, Germany
Universitatsklinikum Frankfurt
🇩🇪Frankfurt am Main, Germany
Bacs-kiskun Megyei Korhaz
đź‡đź‡şKecskemet, Hungary
Pecsi Tudomanyegyetem
đź‡đź‡şPecs, Hungary
NZOZ Osteo-Medic S.C. Artur Racewicz i Jerzy Supronik
🇵🇱Bialystok, Poland
Szpital Uniwersytecki nr 1 im. Dr A. Jurasza
🇵🇱Bydgoszcz, Poland
Centrum Kliniczno Badawcze
🇵🇱Elblag, Poland
Lubelskie Centrum Diagnostyczne
🇵🇱Swidnik, Poland
Przychodnia Specjalistyczna High-Med
🇵🇱Warszawa, Poland
Universitaetsklinik Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Hautarztpraxis
🇩🇪Mahlow, Germany
MensingDerma research GmbH
🇩🇪Hamburg, Germany
Technische Universitaet Muenchen
🇩🇪Muenchen, Germany
Centrum Badawcze Wspolczesnej Terapii
🇵🇱Lodz, Poland
NZOZ Poradnia Dermatologiczno-Wenerologiczna Mediderm
🇵🇱Torun, Poland
Wojskowy Instytut Medyczny
🇵🇱Warszawa, Poland
Semmelweis Egyetem
đź‡đź‡şBudapest, Hungary
Malopolskie Centrum Medyczne
🇵🇱Krakow, Poland
Dermed Centrum Medyczne Sp. z o.o
🇵🇱Lodz, Poland
DermMedica Sp. z o.o.
🇵🇱Wroclaw, Poland
Centrum Medyczne WroMedica
🇵🇱Wroclaw, Poland
University of Alabama Birmingham
🇺🇸Birmingham, Alabama, United States
Southern California Dermatology
🇺🇸Santa Ana, California, United States
Marietta Dermatology Clinical Research
🇺🇸Marietta, Georgia, United States
Oregon Dermatology and Research Center
🇺🇸Portland, Oregon, United States
Clinical Research Center of Connecticut
🇺🇸Danbury, Connecticut, United States
Advanced Medical Research
🇺🇸Atlanta, Georgia, United States
Henry Ford Medical Center
🇺🇸Detroit, Michigan, United States
Central Sooner Research
🇺🇸Norman, Oklahoma, United States
Southern California Permanente Medical Group
🇺🇸Los Angeles, California, United States
MedDerm Associates
🇺🇸San Diego, California, United States
Olympian Clinical Research
🇺🇸Clearwater, Florida, United States
Northshore Universite Healthsystem
🇺🇸Skokie, Illinois, United States
Suzanne Bruce and Associates - The Center for Skin Research
🇺🇸Houston, Texas, United States
Dermatology Clinical Research Center of San Antonio
🇺🇸San Antonio, Texas, United States
Toronto Research Centre
🇨🇦Toronto, Ontario, Canada
Dawes Fretzin Clinical Research Group
🇺🇸Indianapolis, Indiana, United States
Oregon Medical Research Center
🇺🇸Portland, Oregon, United States
Menter Dermatology Research Institute
🇺🇸Dallas, Texas, United States
Progressive Clinical Research
🇺🇸San Antonio, Texas, United States
University of Pittsburgh Department of Dermatology
🇺🇸Pittsburgh, Pennsylvania, United States
Modern Research Associates
🇺🇸Dallas, Texas, United States
Dermatology Associates of Seattle
🇺🇸Seattle, Washington, United States
Austin Dermatology Associates
🇺🇸Austin, Texas, United States
Hosp. Univ. Infanta Leonor
🇪🇸Madrid, Spain
Hosp. Univ. de Basurto
🇪🇸Bilbao Vizcaya, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Reina Sofia
🇪🇸Cordoba, Spain
Hosp. de Manises
🇪🇸Manises, Spain
Hosp. Univ. I Politecni La Fe
🇪🇸Valencia, Spain
Hosp. Provincial de Pontevedra
🇪🇸Pontevedra, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Somerset Skin Centre
🇺🇸Troy, Michigan, United States
North Bay Dermatology Centre
🇨🇦North Bay, Ontario, Canada